3 Stocks to Buy Now With Up to 100% or More Upside Potential
One reason that investors continue to do business with full-service brokerage firms is they generate investment ideas, and when they make a call, they typically have solid reasons and a good thesis to back it up, regardless of whether the ideas is long or short.
Here at 24/7 Wall St., we continually comb through sell-side research generated by the top brokerage firms and banks, looking for ideas that can generate big returns for our readers.
A series of new Stifel reports focus on three companies, all are rated Buy, that have astronomical target prices. While the stocks are not suitable for all accounts, investors with a higher risk tolerance may be very interested in these very speculative calls. Despite the risk involved, some big gains could be in store, even if the companies don’t go all the way to the projected highs.
This top biotech recently posted numbers that surprised Wall Street, and it is a rumored takeover candidate. Clovis Oncology Inc. (NASDAQ: CLVS) is an oncology-focused biotechnology company that launched its first drug, Rubraca, in late 2016. The drug is indicated for the treatment of germline and somatic BRCA-induced ovarian cancer after failing two prior lines of chemotherapy.
The company fully owns rights to Rubraca and is investigating expansion into a broader ovarian cancer market and additional tumor indications. Top analysts have raised their price targets, as many have higher confidence in Rubrica’s potential in BRCA-mutated cancers. A damaged gene in either location can lead to increased risk of cancer, particularly breast or ovarian in women. A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumor suppressor genes.
Physicians also are gaining confidence in Rubraca, and Stifel noted this:
Rubraca maintenance approved in the U.S., thoughts on upcoming QUADRA and SOLO-1 data: Bottom line – Clovis’s Rubraca was approved for maintenance therapy in patients with recurrent ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. This is the same indication that AstraZeneca’s Lynparza as well as Tesaro’s Zejula maintenance are approved. With last Friday’s approval, Clovis will now have access to the larger maintenance setting (versus treatment setting) where an estimated 80% physicians intend to prescribe a PARP inhibitor. We expect a smooth commercial rollout with the new indication as Clovis’s salesforce is simply extending a new indication to the same ovarian cancer doctors they are already calling upon (bodes well for our $166 million/$642 million fiscal year 2018 and 2020 revenue estimates).
The Stifel price target is a stunning $110, and the Wall Street consensus price objective is $86.90. Shares closed on Tuesday at $61.08.